US Venture Partners led a 13m Series A round in Nervonik.

US Venture Partners, a venture capital firm, led a 13m Series A round in Nervonik, a medical device company, with participation from Foothill Ventures, Correlation Ventures, Shangbay Capital, Camford Capital, Joyance Partners, Life Science Angels and Seraph Group. "We are excited to receive this strong support from top institutional investors as we push forward in advancing peripheral nerve stimulation technology. This financing advances our mission to bring a novel solution to millions of people suffering from chronic pain," Aydin Babakhani, Nervonik Founder and CEO.